SAN

76.29

+3.8%↑

ARGX

727.8

+4.69%↑

SHL.DE

34.72

+2.94%↑

PHIA

22.35

+2.05%↑

SRT3

249.6

+2.46%↑

SAN

76.29

+3.8%↑

ARGX

727.8

+4.69%↑

SHL.DE

34.72

+2.94%↑

PHIA

22.35

+2.05%↑

SRT3

249.6

+2.46%↑

SAN

76.29

+3.8%↑

ARGX

727.8

+4.69%↑

SHL.DE

34.72

+2.94%↑

PHIA

22.35

+2.05%↑

SRT3

249.6

+2.46%↑

SAN

76.29

+3.8%↑

ARGX

727.8

+4.69%↑

SHL.DE

34.72

+2.94%↑

PHIA

22.35

+2.05%↑

SRT3

249.6

+2.46%↑

SAN

76.29

+3.8%↑

ARGX

727.8

+4.69%↑

SHL.DE

34.72

+2.94%↑

PHIA

22.35

+2.05%↑

SRT3

249.6

+2.46%↑

Search

Fresenius SE & Co KGaA

Geschlossen

BrancheGesundheitswesen

36.46 1.7

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

35.85

Max

36.76

Schlüsselkennzahlen

By Trading Economics

Einkommen

31M

436M

Verkäufe

-337M

5.8B

KGV

Branchendurchschnitt

13.601

49.888

EPS

0.99

Dividendenrendite

2.96

Gewinnspanne

7.493

Angestellte

177,783

EBITDA

58M

902M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+52.84% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

2.96%

2.38%

Nächstes Ergebnis

5. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-1.7B

21B

Vorheriger Eröffnungskurs

34.76

Vorheriger Schlusskurs

36.46

Nachrichtenstimmung

By Acuity

60%

40%

281 / 344 Ranking in Healthcare

Fresenius SE & Co KGaA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. Aug. 2025, 10:45 UTC

Market Talk
Ergebnisse

Fresenius Beats Subdued Expectations -- Market Talk

Peer-Vergleich

Kursveränderung

Fresenius SE & Co KGaA Prognose

Kursziel

By TipRanks

52.84% Vorteil

12-Monats-Prognose

Durchschnitt 54.96 EUR  52.84%

Hoch 58 EUR

Tief 48 EUR

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Fresenius SE & Co KGaA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

10 ratings

9

Buy

1

Halten

0

Sell

Stimmung

By Acuity

281 / 344 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Fresenius SE & Co KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
help-icon Live chat